Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02341807 · ClinicalTrials.gov registry record · Phase 1
Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations
A Phase 1 study of Choroideremia and CHM (Choroideremia) Gene Mutations, sponsored by Spark Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 3
- Study locations
NCT02341807 is a Phase 1 study of Choroideremia and CHM (Choroideremia) Gene Mutations that has completed, run by Spark Therapeutics. The registered enrollment target is 15 participants, below the 3,132-participant average among 7 other Choroideremia trials with a reported enrollment target (100% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT02341807, a Phase 1 study of Choroideremia and CHM (Choroideremia) Gene Mutations, has completed, sponsored by Spark Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 3
- Study locations
Study Summary
This clinical study evaluates the safety and tolerability of AAV2-hCHM in participants with Choroideremia gene mutations.
Conditions Studied
Interventions
- BIOLOGICAL AAV2-hCHM
Study Locations (3)
Pennsylvania
- University of Pennsylvania - Philadelphia
- Children's Hospital of Philadelphia - Philadelphia
Massachusetts
- Massachusetts Eye and Ear Infirmary - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2015-01-15 |
| Est. Completion | 2022-10-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02341807
The ClinicalTrials.gov registry entry for NCT02341807 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,132-participant average among 7 other Choroideremia trials with a reported enrollment target (100% lower). The listed sponsor is Spark Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Choroideremia appearing as the primary indexed condition, and to 1 intervention - of which AAV2-hCHM is the first listed.
NCT02341807 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Pennsylvania, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02341807 about?
NCT02341807 is a clinical study titled "Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations". This clinical study evaluates the safety and tolerability of AAV2-hCHM in participants with Choroideremia gene mutations.
What is the current status of trial NCT02341807?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2015-01-15. Estimated completion is 2022-10-12.
What conditions does trial NCT02341807 study?
This clinical trial studies the following conditions: Choroideremia, CHM (Choroideremia) Gene Mutations.
What interventions are being tested in trial NCT02341807?
The interventions under investigation include: AAV2-hCHM (BIOLOGICAL).
Who is sponsoring clinical trial NCT02341807?
This trial is sponsored by Spark Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02341807 being conducted?
This trial has 3 study locations across Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Choroideremia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia
ACTIVE NOT RECRUITING · Phase 1
-
Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)
ACTIVE NOT RECRUITING · Phase 1
-
High Resolution Retinal Imaging
RECRUITING
-
Inherited Retinal Degenerative Disease Registry
RECRUITING
-
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
RECRUITING
-
Natural Disease Progression in Participants With Choroideremia
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.